Sanofi Sells Global Rights To Rare Autoimmune Drug Enjaymo For …
WEB9 hours ago · On Friday, Italian pharma company Recordati S.p.A agreed to acquire the global rights to Enjaymo (sutimlimab) from Sanofi SA (NASDAQ:SNY) for $825 million as an upfront payment and additional ...
RECORDATI ANNOUNCES AGREEMENT TO ACQUIRE THE …
WEB18 hours ago · Milan, 4th October 2024 – Recordati today announces an agreement with Sanofi to acquire the global rights to Enjaymo® (sutimlimab), a biologic which is the only approved targeted product for ...
In sustained rare disease push, Recordati lays out $825M upfront …
WEB10 hours ago · Recordati is floating $825 million upfront—plus another $250 million in potential commercial milestones—to get its hands on the global rights to Sanofi’s rare disease biologic Enjaymo.
Recordati buys rights to rare immune disorder drug from Sanofi …
WEBRecordati shares had jumped 5.3% by 0744 GMT, while Sanofi was up 1.3%. The deal is "very positive" as it will lead to optimised production and an increase in revenues for the Italian firm, a ...
Sanofi Drug for Rare Blood Disease Is Heading to Recordati for …
WEB1 day ago · Recordati is paying $825 million up front for global rights to Enjaymo, a drug that is approved in the U.S., Japan, and Europe. If the drug achieves sales milestones, the company could pay out up ...
Recordati to Buy Global Rights to Sanofi's Enjaymo for $825 Million
WEB17 hours ago · Oct 4, 2024 6:47am. By Andrea Figueras. Recordati reached an agreement with French pharmaceutical company Sanofi to acquire the global rights to autoimmune disorder treatment Enjaymo for $825 ...
Recordati to acquire worldwide rights to Sanofi’s antibody Enjaymo
WEB1 day ago · Recordati has reached an agreement with Sanofi for acquiring the worldwide rights to Enjaymo, the only approved treatment specifically targeting cold agglutinin disease (CAD), a rare B-cell lymphoproliferative disorder. The terms of the acquisition include an upfront payment of $825m from Recordati to Sanofi, plus additional milestone payments ...
RECORDATI ANNOUNCES AGREEMENT TO ACQUIRE THE …
WEB1 day ago · Recordati will host a conference call today, 4 th October, at 13:00 CEST (12:00 p.m. GMT) to discuss the agreement to acquire Enjaymo®.The dial-in numbers for the conference call service are ...
RECORDATI ANNOUNCES AGREEMENT TO ACQUIRE THE …
WEB18 hours ago · Milan, 4 th October 2024 – Recordati today announces an agreement with Sanofi to acquire the global rights to Enjaymo® (sutimlimab), a biologic which is the only approved targeted product for the treatment of cold agglutinin disease (CAD), a rare B-cell lymphoproliferative disorder.. Enjaymo® (sutimlimab) is a humanized monoclonal antibody indicated for the treatment of hemolysis in adults ...
Sanofi Offloads Rare Autoimmune Drug to Recordati in
WEB11 hours ago · Sanofi sold Enjaymo, its humanized monoclonal antibody treatment for the rare autoimmune disorder cold agglutinin disease, to Italy’s Recordati in an agreement potentially worth more than $1 billion. Under the terms of the deal, Milan-based Recordati will pay $825 million upfront and will pledge up to $250 million in sales-based milestones.
- Some results have been removed